You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
振東製藥(300158.SZ):2019年業績扭虧為盈至1.43億元 擬10派0.5元
格隆匯 04-23 20:16

格隆匯4月23日丨振東製藥(300158.SZ)披露2019年年度報告,實現營業收入43.99億元,同比增長28.63%;歸屬於上市公司股東的淨利潤1.43億元,上年同期虧損1.47億元;歸屬於上市公司股東的扣除非經常性損益的淨利潤1.27億元,上年同期虧損1.79億元;基本每股收益0.1382元,擬向全體股東每10股派發現金紅利0.5元(含税)。

面對居民健康意識的提升、收入水平和生活質量的提高以及消費者更加關注健康生活,公司攜手分眾傳媒,海量投放樓宇廣告,匯聚“品牌藍海”;高鐵提速,朗迪刷屏,走出“品牌通路”;冠名央視廣告,五大頻道發力,佔據“品牌高空”。大力宣傳推廣朗迪八段錦,讓14億國民愛上朗迪鈣。面對國家西醫禁止開中藥、中成藥監控、醫保控費等政策壓力,公司立足情感營銷、學術推廣和臨牀研究等多種方法,開發、恢復雙策並舉,保證了公司拳頭產品的增長,保留了多個潛力品種的省級醫保資格,實現了較大幅度的增長。

2019年,振東製藥榮獲“年度最具科技創新力中藥企業”、“國家農業產業化重點龍頭企業”、榮獲“2019年中國醫藥工業最具成長力企業”的殊榮,連續5年躋身工信部全國醫藥工業百強榜。

報告期內,公司品牌效應逐步顯現,持續推進精準營銷和學術營銷,提高終端覆蓋和市場放量,從臨牀和OTC兩個業務線同步發力,與電商銷售互牽互引,實現了線上線下同步發展,產品結構不斷優化。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account